Jade Biosciences (JBIO) TD Cowen 46th Annual Health Care Conference summary

Key program updates and clinical development

• Lead asset JADE101, an anti-APRIL antibody for IgA nephropathy, is expected to deliver interim phase I data in the first half of the year, with phase II to start mid-year and data in 2027.

• JADE101 is designed for best-in-class efficacy, high binding affinity, and extended half-life, aiming for six or fewer injections per year.

• JADE201, an afucosylated anti-BAFFR antibody, will enter phase I in RA patients in Q2, with interim data expected in 2027.

• A third program, with an undisclosed target, is set to enter the clinic in the first half of 2027, with target disclosure planned for the second half of this year.

• The company ended 2025 with $336 million in cash, providing runway into the first half of 2028.

Market opportunity and competitive landscape

• IgA nephropathy is a large and growing market, with new KDIGO guidelines and recent approvals expanding the treatable population.

• JADE101 targets maximal APRIL suppression, aiming to outperform current therapies like sibeprylimab and atacicept in efficacy and convenience.

• Preclinical data show JADE101 has over 750-fold higher binding affinity than sibeprylimab and aims for fewer injections per year.

• The anti-APRIL class is expected to become frontline therapy for IgAN, with a focus on deep and durable proteinuria reduction and EGFR stabilization.

• The company is also exploring first-in-class indications in rheumatology and nephrology, including ANCA-associated vasculitis.

Clinical strategy and regulatory outlook

• Phase I data for JADE101 will include robust biomarker analysis, with healthy volunteer PK/PD responses expected to translate directly to patients.

• The dosing strategy leverages a loading dose and maintenance dose every 8 weeks, supported by half-life extension technology.

• The FDA and National Kidney Foundation are convening to discuss ways to accelerate registration pathways for IgAN therapies, potentially shortening timelines.

• Accelerated approval remains viable, with proteinuria reduction as a primary endpoint and EGFR stabilization as a long-term outcome.

• Active comparator arms are unlikely to be required in upcoming registrational trials.